CADTH Canadian Drug Expert Committee final recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes
The Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin not be listed for the treatment of type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
April 27, 2016, 2016
|
Series: | Common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin not be listed for the treatment of type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea |
---|---|
Physical Description: | 1 PDF file (5 pages) |